Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1993-2-4
|
| pubmed:abstractText |
Adjunct therapy with recombinant bovine interleukin-2 and antibiotics for Staphylococcus aureus IMI was investigated in an attempt to improve the therapy of antibiotics alone. Treatment of established S. aureus IMI with Na-cephapirin or Cefa-Lak produced average cures of 32.0 and 41.8%, respectively. When Na-cephapirin treatment was combined with recombinant bovine interleukin-2 at either 3.3 or 10 mg, the therapeutic efficacy was improved by an average of 20 to 30%. When Cefa-Lak treatment was combined with recombinant bovine interleukin-2 at 10 mg, the therapeutic efficacy was improved on average by 20%. Recombinant bovine interleukin-2, formulated in the excipient of the commercial Cefa-Lak, also improved the therapeutic efficacy by 16% compared with Cefa-Lak alone. Recombinant bovine interleukin-2, formulated in Cefa-Lak, maintained biological activity at room temperature for at least 21 d. After intramammary infusion of recombinant bovine interleukin-2, no biologically active interleukin-2 was detected in milk 48 h (four milkings) after administration. These data suggest that cytokines may be used as adjunct therapy with existing mastitis antibiotics or formulations of existing commercial products to improve the therapeutic efficacy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0022-0302
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
75
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3330-8
|
| pubmed:dateRevised |
2003-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:1474202-Animals,
pubmed-meshheading:1474202-Cattle,
pubmed-meshheading:1474202-Cephapirin,
pubmed-meshheading:1474202-Drug Stability,
pubmed-meshheading:1474202-Drug Therapy, Combination,
pubmed-meshheading:1474202-Female,
pubmed-meshheading:1474202-Interleukin-2,
pubmed-meshheading:1474202-Mastitis, Bovine,
pubmed-meshheading:1474202-Milk,
pubmed-meshheading:1474202-Recombinant Proteins,
pubmed-meshheading:1474202-Staphylococcal Infections
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Potentiation of antibiotic therapy for bovine mastitis by recombinant bovine interleukin-2.
|
| pubmed:affiliation |
Agricultural Research Division, American Cyanamid Co., Princeton, NJ 08543-0400.
|
| pubmed:publicationType |
Journal Article
|